Shionogi To File HIV Integrase Inhibitor Dolutegravir In U.S. And Europe By Year End
This article was originally published in PharmAsia News
Executive Summary
Shionogi Pharmaceuticals announced Oct. 4 it plans to file an application for new HIV integrase inhibitor dolutegravir (development code S-349572) in the United States and Europe in 2012.